The motor disorder of multiple system atrophy The term multiple system atrophy was originally proposed by Graham and Oppenheimer' in a paper describing a patient with autonomic failure, cerebellar ataxia and probable pyramidal signs, but no parkinsonism, in life. Pathologically, there was cell loss and gliosis, without Lewy bodies, not only in intermediolateral cell columns, olives, pons and cerebellum, but also in the substantia nigra and the putamen. The term then was developed2 as a common label to include many, but not all, cases of idiopathic orthostatic hypotension,3 or pure autonomic failure (others may have Lewy body disease), Shy-Drager syndrome,4 and autonomic failure associated with olivopontocerebellar atrophy (OPCA),5 and striatonigral degeneration.6 At autopsy, these cases showed involvement of most or all of the above structures to varying degrees.78 Some authors subsequently sought to widen the usage of the term to include other degenerative brain diseases. MSA is a specific condition, however, and only one of a number of "multisystem degenerations". Oppenheimer was willing to consider that MSA may also be familial and, indeed, the pathology of dominantly inherited OPCA could often be difficult to distinguish from that of some cases of sporadic cerebellar-predominant MSA. Clinically, however, there are often important differences. Thus, in some familial cases, pigmentary retinopathy, optic atrophy or dementia,9 and in some others titubation, supranuclear ophthalmoplegia including downgaze, areflexia or cataracts,'0 which are not part of sporadic MSA, may be seen. Another difference is the usual absence of autonomic failure and the generally younger onset and often much longer survival of familial cases of OPCA. The most convincing argument for considering sporadic adult-onset cases of striatonigral degeneration, Shy-Drager syndrome, and OPCA as suffering with one disorder, namely MSA (which is, moreover, distinct from familial OPCA) comes from the recent independent demonstration in such cases by several groups of oligodendrogliall'-' and neuronal" ' Two approaches to characterising the motor disorder of MSA are possible. A prospective study of patients diagnosed in life as MSA should give good clinical data, but might involve some degree of diagnostic uncertainty. An alternative approach is to attempt to build up a clinical picture of the disease from pathologically confirmed cases. For this review, we have chosen the second method. Thus, the data we present here are based upon 188 cases of pathologically proven MSA'9 (sporadic adult-onset cases showing striatonigral or olivopontocerebellar atrophy at autopsy, or both-reference list available from the authors on request) for whom reasonable information on the presence or absence of key clinical features was available. We recognise, however, that insistence on pathological verification necessarily limits the clinical information available, just as prospective clinical studies may be criticised for the lack of pathology.
The major elements of the motor disorder of MSA were, first and foremost, parkinsonism (89%), followed by cerebellar signs (56%) and pyramidal signs (62 5%). It might generally be considered easy to decide whether or not a patient has parkinsonism, a cerebellar syndrome, or pyramidal signs, and indeed when each is seen in isolation this is usually the case. Problems arise, however, when, as in MSA, more than one motor system may be affected. 
Parkinsonism
of pure autonomic failure persisting to death due to MSA has since been reported). Among the subjects with "pure" parkinsonism the ratio of patients with, to those without, autonomic failure was 1 1:1, but where both pyramidal and cerebellar signs were also present the ratio was 10 6: 1. This may signify a correlation between brainstem pathology and autonomic failure. Alternatively, autonomic symptoms may simply not have been noted in the absence of other atypical features.
Of all the cases with autonomic failure, 88% had parkinsonism, 67% had pyramidal signs, and 62% had cerebellar signs.
Presentation and clinical course of patients with MSA and parkinsonism It is parkinsonism that most commonly brings the patient with MSA to medical attention, so most patients are initially diagnosed as, and treated for, idiopathic Parkinson's disease. The clues at presentation are often few and subtle. Moreover outpatients with parkinsonism usually undergo a full neurological examination only on their first visit, to be subsequently repeated only if they spontaneously complain of early falls, or postural faintness or blackouts, or fail to respond to levodopa, or are admitted to hospital.
At the first visit, tendon reflexes may be brisk, with either normal or equivocal plantar responses. The finding of extensor plantar responses is often put down to coincidental cervical spondylotic myelopathy, and sometimes myelography or spinal MRI is performed. Although there may be no tremor, or even a tremor at rest, it is more common to find a fine postural and action tremor. In many patients this may assume a rather irregular, jerky, character, and, on careful examination, some or all of it may be found to be due to discrete myoclonic jerks of the fingers which are often stretch-sensitive.27 Dementia28 and seizures are not part of MSA, although gliall"-15 and neuronal"5-17 inclusions can be found in both cortical and subcortical structures. Early gait instability is a useful clinical clue, and clear cerebellar signs at the initial consultation should strongly suggest the possibility of MSA.
Usually, subtle atypical features are not picked up early on, and levodopa treatment is soon instituted for presumed idiopathic Parkinson's disease. A poor or absent response to an adequate dose of levodopa given for an adequate period of time is frequent in MSA, although a moderate, or even a (usually transient) dramatic, response is seen in some patients.2930 Thus the diagnosis is usually first questioned when the patient shows an atypical response to treatment. Much earlier in the disease the response to a single 250 mg dose of levodopa (with a peripheral decarboxylase inhibitor) is a good (but imperfect) predictor of subsequent dopaminergic responsiveness, and is superior to the apomorphine test in this regard."3 The association of such challenge tests with iodobenzamide single positron emission CT32 or 1 5 T MRI33 may prove useful in identifying "de-novo" patients with non-idiopathic disease. A pathological external urethral or anal sphincter EMG is also highly suggestive of MSA. 34 Dopamine agonists are usually no more effective than levodopa in MSA, although some patients may tolerate them better. Anticholinergics must be used with due regard to the urinary status. We have found amantadine to be useful in some patients, perhaps because of downstream NMDA-receptor antagonist effects. Finally it is important to note that, particularly because of the absence of short-term fluctuations, many patients may appear to be deriving no benefit from their therapy, yet deteriorate alarmingly hours or days after stopping it. 30 Patients with MSA often also lack typical, or display atypical, levodopa-induced dyskinesias on chronic levodopa treatment. Sustained dystonic spasms of facial muscles,30 particularly when unilateral,'35 or predominantly torticollic movements, are often seen. The occurrence of dystonia in MSA as a feature of the disease itself, rather than as a consequence of treatment, is controversial.'6 Some patients, usually late in the disease, develop a relatively fixed and disproportionate antecollis37 which often develops subacutely and may worsen throughout the day. This feature, however, is not pathognomonic of MSA. Distal contractures into fixed "dystonic" postures may occasionally be seen.
Whether major clinical involvement of anterior horn cells or somatic peripheral nerves is an integral part of the disease is controversial. Shy and Drager's original pathologically proven case 2 had neither fasciculations, nor atrophy, nor any loss of tendon reflexes, although the first two features were noted in their case 1, for whom there was no pathology. 4 Cohen et aP8 found mild or asymptomatic distal sensorimotor polyneuropathy in seven of 36 patients diagnosed as MSA, with "relatively mild" electrical abnormalities. The significance of these findings in a minority of patients, who are often already wheelchair-bound, remains obscure.
As the disease progresses, the pyramidal, cerebellar, and speech deficits outlined above often appear gradually. The spouse may report excessive snoring or respiratory stridor, first during sleep and later also during the day. Occasional involuntary inspiratory sighs may also occur. Tracheostomy is sometimes indicated, but in very advanced MSA this is a difficult ethical decision.
Regardless of how the condition starts, the clinical picture of most patients with MSA converges in the advanced stages towards a "full house". In the fully developed disease they are permanently chair-or bedbound, often with an indwelling catheter because they can no longer intermittently self-catheterise, almost mute and severely dysphagic, yet with retained intellect and awareness. Of 19 patients with MSA from the UK Parkinson's Disease Society Brain Bank for whom cause of death was noted at autopsy, 15 died of bronchopneumonia.
Survival from first symptom to death is variable, but the disease significantly shortens life. Among 217 pathologically confirmed cases described in published reports before 1990, median survival, as judged from the case reports, was only 5-5 (range 1-14) years. Median survival of 35 cases in the UK Brain Bank was 7-3 (2-15) years, however, and in our own series of 100 prospectively followed patients, is 9-5 (1-5-20) years. One pathologically proven patient in our series died after 15 years of disease, and one of Rajput et al39 after more than 18 years.
The challenge now is to understand the cause and to develop an effective treatment for this miserable illness. A useful practical review of current treatment.
